Resmed (RMD) Stock
Sleep apnea device giant with digital health services. Here's the price, business snapshot, and what's worth knowing about Resmed in October 2026.
ResMed Inc. (RMD) is a global medical‑technology company best known for devices that treat sleep apnoea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It sells CPAP machines, masks, ventilators and a growing suite of cloud-connected software and services aimed at long‑term patient management. Revenue mixes device sales, consumables and recurring digital subscriptions — a model that can support predictable cash flow as the installed base and mask/consumable replacements continue. Key attractions for investors include an ageing population, steady demand for sleep solutions, and ResMed’s push into remote-monitoring and digital health. Risks include reimbursement changes, competition from other device makers, supply‑chain pressures and regulatory approvals; performance can vary and past results do not guarantee future returns. Market cap is about $39.1bn, making it a large-cap healthcare name. This is general educational information, not personalised advice — consider your personal circumstances and tolerance for volatility before investing.
Why It’s Moving
ResMed Highlights Strong Sleep Therapy Demand and EPS Growth Outlook
- The company targets 12%-14% EPS growth, driven by increased demand for sleep therapy solutions.
- Executives highlighted the positive impact of GLP-1 patients on sleep apnea treatment needs.
- Growth strategy centers on ongoing product innovation and improving patient adherence rates.
ResMed Highlights Strong Sleep Therapy Demand and EPS Growth Outlook
- The company targets 12%-14% EPS growth, driven by increased demand for sleep therapy solutions.
- Executives highlighted the positive impact of GLP-1 patients on sleep apnea treatment needs.
- Growth strategy centers on ongoing product innovation and improving patient adherence rates.
Sixth Month Growth Performance
When is the next earnings date for RESMED INC (RMD)?
ResMed has not yet confirmed a specific date for its next earnings release. Based on the historical reporting pattern, which typically follows a quarterly cadence of approximately three months after the previous report, the next announcement is expected in late October 2026. This upcoming report will cover the company's fiscal third quarter results. Investors should monitor official channels for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ResMed's stock with a target price of $239.71, indicating potential growth.
Financial Health
ResMed is performing well with strong revenue, cash flow, and profit margins, indicating solid financial stability.
Dividend
ResMed's low dividend yield of 1.1% suggests limited returns for dividend-seeking investors. If you invested $1000 you would be paid $11 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring revenue model
ResMed’s mix of devices plus consumables and subscriptions can create steadier cash flows, though revenues still face reimbursement and demand risks.
Global patient base
An ageing population and rising diagnosis of sleep disorders support long-term demand, but regional regulation and payor policies can affect growth.
Connected‑care push
Investment in cloud platforms and remote monitoring could boost stickiness and services revenue, yet technology adoption and competition may vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
